Histological tumor response to neoadjuvant chemotherapy correlates to Immunoscore in colorectal cancer liver metastases patients

2021 ◽  
Author(s):  
Chong Zhang ◽  
Xiangyu Wang ◽  
Jiahao Han ◽  
Rui Zhang ◽  
Zhenmei Chen ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Neoadjuvant Chemotherapy ◽  
Liver Metastases ◽  
Tumor Response ◽  
Colorectal Cancer Liver Metastases ◽  
Response To Neoadjuvant Chemotherapy

scholarly journals Importance of response to neoadjuvant chemotherapy in potentially curable colorectal cancer liver metastases

BMC Cancer ◽  
2008 ◽  
Vol 8 (1) ◽  
Author(s):  
Birgit Gruenberger ◽  
Werner Scheithauer ◽  
Robert Punzengruber ◽  
Christoph Zielinski ◽  
Dietmar Tamandl ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Neoadjuvant Chemotherapy ◽  
Liver Metastases ◽  
Colorectal Cancer Liver Metastases ◽  
Response To Neoadjuvant Chemotherapy

scholarly journals Updates of colorectal cancer liver metastases therapy: review on DEBIRI

2020 ◽  
Vol 7 (1) ◽  
pp. HEP16 ◽  
Author(s):  
Giammaria Fiorentini ◽  
Donatella Sarti ◽  
Roberto Nani ◽  
Camillo Aliberti ◽  
Caterina Fiorentini ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Liver Metastases ◽  
Systemic Chemotherapy ◽  
Tumor Response ◽  
Public Health Issue ◽  
Advanced Stage ◽  
Stage At Diagnosis ◽  
Colorectal Cancer Liver Metastases ◽  
Safety And Efficacy ◽  
Metastatic Sites

Colorectal cancer is a worldwide public health issue, presenting an advanced stage at diagnosis in more than 20% of patients. Liver metastases are the most common metastatic sites and are not indicated for resection in 80% of cases. Unresectable colorectal cancer liver metastases that are refractory to systemic chemotherapy may benefit from transarterial chembolization with irinotecan-loaded beads (DEBIRI). Several studies show the safety and efficacy of DEBIRI for the treatment of colorectal cancer liver metastases. The development of transarterial chembolization and the introduction of new embolics have contributed to better outcomes of DEBIRI. This article reviews the current literature on DEBIRI reporting its use, efficacy in terms of tumor response and survival and side effects.

Bevacizumab-based neoadjuvant chemotherapy for colorectal cancer liver metastases: Pitfalls and helpful tricks in a review for clinicians

2015 ◽  
Vol 95 (3) ◽  
pp. 272-281 ◽  
Author(s):  
Filippo Pietrantonio ◽  
Armando Orlandi ◽  
Alessandro Inno ◽  
Valentina Da Prat ◽  
Daniele Spada ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Neoadjuvant Chemotherapy ◽  
Liver Metastases ◽  
Colorectal Cancer Liver Metastases

scholarly journals Transarterial chemoembolization alone or followed by bevacizumab for treatment of colorectal liver metastases

2021 ◽  
pp. HEP40
Author(s):  
Giammaria Fiorentini ◽  
Donatella Sarti ◽  
Michele Nardella ◽  
Riccardo Inchingolo ◽  
Massimiliano Nestola ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Liver Metastases ◽  
Disease Control ◽  
Transarterial Chemoembolization ◽  
Tumor Response ◽  
Progression Free Survival ◽  
Disease Control Rate ◽  
Kras Mutations ◽  
Colorectal Cancer Liver Metastases ◽  
Mutational Status

Aims: Bevacizumab (B) in association with systemic chemotherapy is commonly used for the treatment of colorectal cancer liver metastases. The aim of this study was to monitor tumor response, overall survival (OS) and progression-free survival (PFS) of patients with colorectal cancer liver metastases treated with transarterial chemoembolization (TACE) + B compared with TACE alone and to correlate the results with KRAS mutational status. Patients & methods: This was an observational multicentric case–control study (NCT03732235) on the efficacy and safety of B administered after TACE. Results: The disease control rate was significantly higher for the TACE + B than the TACE alone group (p < 0.001). KRAS wild-type patients had a significantly better disease control rate than those with KRAS mutations in the TACE + B group. Median OS and PFS were similar for the TACE + B and TACE groups, whereas median time to progression was significantly higher for the TACE + B group (p < 0.01). Conclusion: The combination of TACE with B may improve tumor response and delay disease progression.

Sign in / Sign up

Export Citation Format

Share Document